|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang C, Cintra M, Brennan K, Zhou M,
Colevas AD, Fischbein N, Zhu S and Gevaert O: Development and
validation of radiomic signatures of head and neck squamous cell
carcinoma molecular features and subtypes. EBioMedicine. 45:70–80.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu Q, Wang C, Li B, Kim K, Li J, Mao M,
Qin L, Li H, Huang X, Xing R, et al: The impact of age on oral
squamous cell carcinoma: A longitudinal cohort study of 2,782
patients. Oral Dis. 25:730–741. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Y, Zhao Q, Ding G, Zhu Y, Li W and
Chen W: Incidence and mortality of laryngeal cancer in China,
2008–2012. Chin J Cancer Res. 30:299–306. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin Y and Yang Y: Bioinformatics-based
discovery of PYGM and TNNC2 as potential biomarkers of head and
neck squamous cell carcinoma. Biosci Rep Jul. 39:BSR201916122019.
View Article : Google Scholar
|
|
6
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghantous Y and Abu Elnaaj I: Global
incidence and risk factors of oral cancer. Harefuah. 156:645–649.
2017.(In Hebrew). PubMed/NCBI
|
|
8
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou C, Shen Z, Ye D, Li Q, Deng H, Liu H
and Li J: The association and clinical significance of CDKN2A
promoter methylation in head and neck squamous cell carcinoma: A
meta-analysis. Cell Physiol Biochem. 50:868–882. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stjernstrøm KD, Jensen JS, Jakobsen KK,
Grønhøj C and von Buchwald C: Current status of human
papillomavirus positivity in oropharyngeal squamous cell carcinoma
in Europe: A systematic review. Acta Otolaryngol. 139:1112–1116.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gaździcka J, Gołąbek K, Strzelczyk JK and
Ostrowska Z: Epigenetic modifications in head and neck cancer.
Biochem Genet. 58:213–244. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhat S, Kabekkodu SP, Jayaprakash C,
Radhakrishnan R, Ray S and Satyamoorthy K: Gene promoter-associated
CpG island hypermethylation in squamous cell carcinoma of the
tongue. Virchows Arch. 470:445–454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferlazzo N, Currò M, Zinellu A, Caccamo D,
Isola G, Ventura V, Carru C, Matarese G and Ientile R: Influence of
MTHFR genetic background on p16 and MGMT methylation in oral
squamous cell cancer. Int J Mol Sci. 18:7242017. View Article : Google Scholar
|
|
14
|
Wang K, Zheng M and Ren Y: Overexpression
of TRMT12 may independently predict poor overall survival in
patients with head and neck squamous cell carcinoma. OncoTargets
Ther. 12:7269–7279. 2019. View Article : Google Scholar
|
|
15
|
Liu C, Guo T, Xu G, Sakai A, Ren S,
Fukusumi T, Ando M, Sadat S, Saito Y, et al: Characterization of
alternative splicing events in HPV-negative head and neck squamous
cell carcinoma identifies an oncogenic DOCK5 variant. Clin Cancer
Res. 24:5123–5132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li R, Ochs MF, Ahn SM, Hennessey P, Tan M,
Soudry E, Gaykalova DA, Uemura M, Brait M, Shao C, et al:
Expression microarray analysis reveals alternative splicing of
LAMA3 and DST genes in head and neck squamous cell carcinoma. PLoS
One. 9:e912632014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu C, Guo T, Sakai A, Ren S, Fukusumi T,
Ando M, Sadat S, Saito Y and Califano JA: A novel splice variant of
LOXL2 promotes progression of human papillomavirus-negative head
and neck squamous cell carcinoma. Cancer. 126:737–748. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kelley DZ, Flam EL, Guo T, Danilova LV,
Zamuner FT, Bohrson C, Considine M, Windsor EJ, Bishop JA, Zhang C,
et al: Functional characterization of alternatively spliced GSN in
head and neck squamous cell carcinoma. Transl Res. 202:109–119.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li ZX, Zheng ZQ, Wei ZH, Zhang LL, Li F,
Lin L, Liu RQ, Huang XD, Lv JW, Chen FP, et al: Comprehensive
characterization of the alternative splicing landscape in head and
neck squamous cell carcinoma reveals novel events associated with
tumorigenesis and the immune microenvironment. Theranostics.
9:7648–7665. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Licitra L, Mesia R, Rivera F, Remenár É,
Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, et
al: Evaluation of EGFR gene copy number as a predictive biomarker
for the efficacy of cetuximab in combination with chemotherapy in
the first-line treatment of recurrent and/or metastatic squamous
cell carcinoma of the head and neck: EXTREME study. Ann Oncol.
22:1078–1087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE,
Even C, et al: Nivolumab vs investigator's choice in recurrent or
metastatic squamous cell carcinoma of the head and neck: 2-year
long-term survival update of CheckMate 141 with analyses by tumor
PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bauml J, Seiwert TY, Pfister DG, Worden F,
Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al:
Pembrolizumab for platinum- and cetuximab-refractory head and neck
cancer: Results from a single-arm, phase II study. J Clin Oncol.
35:1542–1549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Napolitano M, Schipilliti FM, Trudu L and
Bertolini F: Immunotherapy in head and neck cancer: The great
challenge of patient selection. Crit Rev Oncol Hematol.
144:1028292019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kao HF and Lou PJ: Immune checkpoint
inhibitors for head and neck squamous cell carcinoma: Current
landscape and future directions. Head Neck. 41 (Suppl 1):4–18.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Lippman SM, Lee JJ, Yang H, Khuri
FR, Kim E, Lin J, Chang DW, Lotan R, Hong WK, et al: Genetic
variations in regulator of G-protein signaling genes as
susceptibility loci for second primary tumor/recurrence in head and
neck squamous cell carcinoma. Carcinogenesis. 31:1755–1761. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y,
Yang H, Khuri FR, Kim E, Gu J, Lotan R, et al: Novel susceptibility
loci for second primary tumors/recurrence in head and neck cancer
patients: Large-scale evaluation of genetic variants. Cancer Prev
Res (Phila). 2:617–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thomson R, Genovese G, Canon C, Kovacsics
D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo
A, et al: Evolution of the primate trypanolytic factor APOL1. Proc
Natl Acad Sci USA. 111:E2130–E2139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riella C, Siemens TA, Wang M, Campos RP,
Moraes TP, Riella LV, Friedman DJ, Riella MC and Pollak MR:
APOL1-associated kidney disease in Brazil. Kidney Int Rep.
4:923–929. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Freedman BI, Spainhour M, Hicks PJ, Turner
J, Robertson J, Langefeld CD, Murea M and Divers J: Nephropathy
progression in African Americans with a family history of ESKD:
Implications for Clinical Trials in APOL1-associated nephropathy.
Am J Kidney Dis. 74:284–286. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Franceschini N, Kopp JB, Barac A, Martin
LW, Li Y, Qian H, Reiner AP, Pollak M, Wallace RB, Rosamond WD, et
al: Association of APOL1 with heart failure with preserved ejection
fraction in postmenopausal African American women. JAMA Cardiol.
3:712–720. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fontaine F, Lecordier L, Vanwalleghem G,
Uzureau P, Van Reet N, Fontaine M, Tebabi P, Vanhollebeke B,
Büscher P, Pérez-Morga D, et al: APOLs with low pH dependence can
kill all African trypanosomes. Nat Microbiol. 2:1500–1506. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okamoto K, Rausch JW, Wakashin H, Fu Y,
Chung JY, Dummer PD, Shin MK, Chandra P, Suzuki K, Shrivastav S, et
al: APOL1 risk allele RNA contributes to renal toxicity by
activating protein kinase R. Commun Biol. 1:1882018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu X, Zheng W, Wang W, Shen H, Liu L, Lou
W, Wang X and Yang P: A new panel of pancreatic cancer biomarkers
discovered using a mass spectrometry-based pipeline. Br J Cancer.
117:1846–1854. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
O'Toole JF, Bruggeman LA, Madhavan S and
Sedor JR: The cell biology of APOL1. Semin Nephrol. 37:538–545.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kardideh B, Samimi Z, Norooznezhad F,
Kiani S and Mansouri K: Autophagy, cancer and angiogenesis: Where
is the link? Cell Biosci. 9:652019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Codogno P and Morel E: FOXO3a provides a
quickstep from autophagy inhibition to apoptosis in cancer therapy.
Dev Cell. 44:537–539. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tao Q and Chan AT: Nasopharyngeal
carcinoma: Molecular pathogenesis and therapeutic developments.
Expert Rev Mol Med. 9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sticht C, Freier K, Knöpfle K,
Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S and Lichter P:
Activation of MAP kinase signaling through ERK5 but not ERK1
expression is associated with lymph node metastases in oral
squamous cell carcinoma (OSCC). Neoplasia. 10:462–470. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Estilo CL, O-charoenrat P, Talbot S, Socci
ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y,
Boyle JO, et al: Oral tongue cancer gene expression profiling:
Identification of novel potential prognosticators by
oligonucleotide microarray analysis. BMC Cancer. 9:112009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lian M, Fang J, Han D, Ma H, Feng L, Wang
R and Yang F: Microarray gene expression analysis of tumorigenesis
and regional lymph node metastasis in laryngeal squamous cell
carcinoma. PLoS One. 8:e848542013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Uhlen M, Zhang C, Lee S, Sjöstedt E,
Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et
al: A pathology atlas of the human cancer transcriptome. Science.
357:eaan25072017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thul PJ, Åkesson L, Wiking M, Mahdessian
D, Geladaki A, Blal HA, Alm T, Asplund A, Björk L, Breckels LM, et
al: A subcellular map of the human proteome. Science.
356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang SH and O'Sullivan B: Overview of the
8th edition TNM classification for head and neck cancer. Curr Treat
Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhaorigetu S, Wan G, Kaini R, Jiang Z and
Hu CA: ApoL1, a BH3-only lipid-binding protein, induces autophagic
cell death. Autophagy. 4:1079–1082. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ho CJ and Gorski SM: Molecular nechanisms
underlying autophagy-mediated treatment resistance in Cancer.
Cancers (Basel). 11:17752019. View Article : Google Scholar
|
|
48
|
O'Toole JF, Schilling W, Kunze D, Madhavan
SM, Konieczkowski M, Gu Y, Luo L, Wu Z, Bruggeman LA and Sedor JR:
ApoL1 overexpression drives variant-independent cytotoxicity. J Am
Soc Nephrol. 29:869–879. 2018.PubMed/NCBI
|
|
49
|
Kruzel-Davila E, Shemer R, Ofir A,
Bavli-Kertselli I, Darlyuk-Saadon I, Oren-Giladi P, Wasser WG,
Magen D, Zaknoun E, Schuldiner M, et al: APOL1-mediated cell injury
involves disruption of conserved trafficking processes. J Am Soc
Nephrol. 28:1117–1130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng D, Weckerle A, Yu Y, Ma L, Zhu X,
Murea M, Freedman BI, Parks JS and Shelness GS: Biogenesis and
cytotoxicity of APOL1 renal risk variant proteins in hepatocytes
and hepatoma cells. J Lipid Res. 56:1583–1593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Khatua AK, Cheatham AM, Kruzel ED, Singhal
PC, Skorecki K and Popik W: Exon 4-encoded sequence is a major
determinant of cytotoxicity of apolipoprotein L1. Am J Physiol Cell
Physiol. 309:C22–C37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Beckerman P, Bi-Karchin J, Park AS, Qiu C,
Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA,
et al: Transgenic expression of human APOL1 risk variants in
podocytes induces kidney disease in mice. Nat Med. 23:429–438.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kumar V, Paliwal N, Ayasolla K, Vashistha
H, Jha A, Chandel N, Chowdhary S, Saleem MA, Malhotra A, Chander
PN, et al: Disruption of APOL1-miR193a axis induces disorganization
of podocyte actin cytoskeleton. Sci Rep. 9:35822019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kumar V, Ayasolla K, Jha A, Mishra A,
Vashistha H, Lan X, Qayyum M, Chinnapaka S, Purohit R, Mikulak J,
et al: Disrupted apolipoprotein L1-miR193a axis dedifferentiates
podocytes through autophagy blockade in an APOL1 risk milieu. Am J
Physiol Cell Physiol. 317:C209–C225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bruno J, Pozzi N, Oliva J and Edwards JC:
Apolipoprotein L1 confers pH-switchable ion permeability to
phospholipid vesicles. J Biol Chem. 292:18344–18353. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Shah SS, Lannon H, Dias L, Zhang JY, Alper
SL, Pollak MR and Friedman DJ: APOL1 kidney risk variants induce
cell death via mitochondrial translocation and opening of the
mitochondrial permeability transition pore. J Am Soc Nephrol.
30:2355–2368. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Davis SE, Khatua AK and Popik W:
Nucleosomal dsDNA Stimulates APOL1 expression in human cultured
podocytes by activating the cGAS/IFI16-STING signaling pathway. Sci
Rep. 9:154852019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Choi AM, Ryter SW and Levine B: Autophagy
in human health and disease. N Engl J Med. 368:651–662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kundu M and Thompson CB: Autophagy: Basic
principles and relevance to disease. Annu Rev Pathol. 3:427–455.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Antunes F, Erustes AG, Costa AJ,
Nascimento AC, Bincoletto C, Ureshino RP, Pereira GJ and Smaili SS:
Autophagy and intermittent fasting: The connection for cancer
therapy? Clinics (Sao Paulo). 73 (Suppl 1):e814s2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Salminen A, Kaarniranta K and Kauppinen A:
Beclin 1 interactome controls the crosstalk between apoptosis,
autophagy and inflammasome activation: Impact on the aging process.
Ageing Res Rev. 12:520–534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yu L, Chen Y and Tooze SA: Autophagy
pathway: Cellular and molecular mechanisms. Autophagy. 14:207–215.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Levy JM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chidiac M, Fayyad-Kazan M, Daher J,
Poelvoorde P, Bar I, Maenhaut C, Delrée P, Badran B and Vanhamme L:
ApolipoproteinL1 is expressed in papillary thyroid carcinomas.
Pathol Res Pract. 212:631–635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hu CA, Klopfer EI and Ray PE: Human
apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
FEBS Lett. 586:947–955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xu Y, Liu J, Nipper M and Wang P: Ductal
vs. acinar? Recent insights into identifying cell lineage of
pancreatic ductal adenocarcinoma. Ann Pancreat Cancer. Jun
17–2019.(Epub ahead of print). doi: 10.21037/apc.2019.06.03.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang J, Jia L, Tsang CM and Tsao SW: EBV
infection and glucose metabolism in nasopharyngeal carcinoma. Adv
Exp Med Biol. 1018:75–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Elgui de Oliveira D, Müller-Coan BG and
Pagano JS: Viral carcinogenesis beyond malignant Transformation:
EBV in the progression of human cancers. Trends Microbiol.
24:649–664. 2016. View Article : Google Scholar : PubMed/NCBI
|
